Displaying 61 - 80 of 554
Endo Pharmaceuticals Inc./Amneal Pharmaceuticals, Inc.
The FTC is suing Endo Pharmaceuticals, Inc., Endo International plc, Impax Laboratories, LLC, and Impax’s owner, Amneal Pharmaceuticals, Inc., alleging that a 2017 agreement between Endo and Impax violated the antitrust laws by eliminating competition in the market for oxymorphone ER. The complaint charges the defendants with violating Sections 1 and 2 of the Sherman Act, which constitutes unfair methods of competition in violation of Section 5 of the FTC Act. Specifically, Endo, Impax, and Amneal are charged with entering into an illegal agreement in restraint of trade, and Amneal is charged with monopolization of the oxymorphone ER market. The complaint was filed in the U.S. District Court for the District of Columbia on Jan. 25, 2021.
Prudential Security, et al., In the Matter of
FTC Approves Final Orders Requiring Two Glass Container Manufacturers to Drop Noncompete Restrictions That They Imposed on Workers
Ardagh Group, et al., In the Matter of
O-I Glass, Inc., In the Matter of
FTC to Host Forum on February 16 Examining Its Proposed Rule to Ban Noncompete Restrictions
FTC Releases Final Agenda for Feb. 16 Public Forum on Its Proposed Rule to Ban Noncompete Restrictions
FTC Asks Federal Court to Hold ‘Pharma Bro’ Martin Shkreli in Contempt
Dissenting Statement of Commissioner Christine S. Wilson Concerning the Notice of Proposed Rulemaking for the Non-Compete Clause Rule
Statement of Commissioners Rebecca Kelly Slaughter and Alvaro M. Bedoya Concerning the Notice of Proposed Rulemaking for the Non-Compete Clause Rule
Non-Compete Clause Rulemaking
Dissenting Statement of Commissioner Christine S. Wilson Regarding the Matter of Prudential Security
2022 Report on Ethanol Market Concentration
Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC
San Juan, IPA, In the Matter of
San Juan IPA, Inc., a physicians’ independent practice association operating in northwestern New Mexico, agreed to settle Commission charges that it orchestrated and carried out agreements among its member doctors to set the price that they would accept from health plans, to bargain collectively to obtain the group’s desired price terms, and to refuse to deal with health plans except on collectively determined price terms. According to the complaint, the effect of this conduct was higher prices for medical services for the area’s consumers. The consent order prohibits the association from collectively negotiating with health plans on behalf of its physicians and from setting their terms of dealing with such purchasers. This consent involves 120 physicians who make up about 80 percent of the doctors practicing independently in the area of Farmington, New Mexico.
Federal Trade Commission, DOJ Urge FERC to Preserve Robust Wholesale Electricity Markets
Displaying 61 - 80 of 554